BC Week In Review | Sep 1, 2017
Clinical News

EC approves bene-Arzneimittel's Elmiron for bladder pain

In June, bene-Arzneimittel GmbH (Munich, Germany) said the European Commission approved Elmiron pentosan polysulfate sodium to treat bladder pain syndrome. The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) markets the drug in the...
BC Extra | Oct 23, 2015
Company News

Imprimis offers Turing competitor

Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) said it launched a low-cost alternative to toxoplasmosis drug Daraprim pyrimethamine from Turing Pharmaceuticals AG (New York, N.Y.). Imprimis priced its compounded formulation of pyrimethamine and leucovorin at $99 per 100-count...
BC Week In Review | Oct 31, 2005
Company News

Bayer, J&J deal

The companies partnered to co-develop and co-commercialize BAYG's BAY 59-7939 to prevent and treat thrombosis. The Factor Xa inhibitor is in Phase IIb trials to prevent venous thromboembolism after major orthopedic surgery, to treat venous...
BC Extra | Oct 27, 2005
Company News

JNJ in-licenses BAYG thrombosis compound

Johnson & Johnson (JNJ) and Bayer (FSE:BAYG; BAY) partnered to co-develop and co-commercialize BAYG's BAY 59-7939 to prevent and treat thrombosis. The Factor Xa inhibitor is in Phase IIb trials to prevent venous thromboembolism after...
BC Week In Review | Oct 13, 1997
Company News

Alza, Ivax deal

AZA completed its acquisition of IVX's rights in the U.S. and Canada to Elmiron (pentosan polysulfate sodium) and three additional urology products Alza Corp. (AZA), Palo Alto, Calif.   Ivax Corp. (IVX), Miami, Fla.  ...
BC Week In Review | Sep 22, 1997
Company News

Alza, Ivax deal

AZA will acquire from Ivax the U.S. and Canadian rights to Elmiron (pentosal polysulfate sodium) and three additional urology products for $75 million. AZA could pay additional fees over the next five years based on...
BioCentury | Sep 22, 1997
Analyst Picks & Changes

Analyst picks & changes

Alza Corp. (AZA), Palo Alto, Calif. Business: Drug Delivery Hambrecht & Quist analyst Alex Zisson estimated that AZA's acquisition of a family of urology drugs from Ivax Corp. could add $0.15 to EPS from Elmiron,...
Items per page:
1 - 7 of 7